Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.18
NVSEF's Cash to Debt is ranked lower than
88% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.46 vs. NVSEF: 0.18 )
Ranked among companies with meaningful Cash to Debt only.
NVSEF' s Cash to Debt Range Over the Past 10 Years
Min: 0.18  Med: 1.23 Max: N/A
Current: 0.18
Equity to Asset 0.54
NVSEF's Equity to Asset is ranked lower than
55% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.62 vs. NVSEF: 0.54 )
Ranked among companies with meaningful Equity to Asset only.
NVSEF' s Equity to Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.58 Max: 0.65
Current: 0.54
0.51
0.65
Interest Coverage 12.78
NVSEF's Interest Coverage is ranked lower than
61% of the 458 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.68 vs. NVSEF: 12.78 )
Ranked among companies with meaningful Interest Coverage only.
NVSEF' s Interest Coverage Range Over the Past 10 Years
Min: 13.42  Med: 16.60 Max: 30.91
Current: 12.78
13.42
30.91
F-Score: 4
Z-Score: 2.21
M-Score: -2.70
WACC vs ROIC
8.65%
7.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 17.27
NVSEF's Operating margin (%) is ranked higher than
79% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.77 vs. NVSEF: 17.27 )
Ranked among companies with meaningful Operating margin (%) only.
NVSEF' s Operating margin (%) Range Over the Past 10 Years
Min: 17.81  Med: 20.94 Max: 22.35
Current: 17.27
17.81
22.35
Net-margin (%) 13.55
NVSEF's Net-margin (%) is ranked higher than
96% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.28 vs. NVSEF: 13.55 )
Ranked among companies with meaningful Net-margin (%) only.
NVSEF' s Net-margin (%) Range Over the Past 10 Years
Min: 15.06  Med: 19.02 Max: 35.29
Current: 13.55
15.06
35.29
ROE (%) 8.88
NVSEF's ROE (%) is ranked higher than
87% of the 739 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.27 vs. NVSEF: 8.88 )
Ranked among companies with meaningful ROE (%) only.
NVSEF' s ROE (%) Range Over the Past 10 Years
Min: 12.6  Med: 15.32 Max: 25.73
Current: 8.88
12.6
25.73
ROA (%) 5.06
NVSEF's ROA (%) is ranked higher than
86% of the 763 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.85 vs. NVSEF: 5.06 )
Ranked among companies with meaningful ROA (%) only.
NVSEF' s ROA (%) Range Over the Past 10 Years
Min: 7.21  Med: 8.97 Max: 16.18
Current: 5.06
7.21
16.18
ROC (Joel Greenblatt) (%) 48.46
NVSEF's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.64 vs. NVSEF: 48.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVSEF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 39.09  Med: 59.62 Max: 69.76
Current: 48.46
39.09
69.76
Revenue Growth (3Y)(%) 1.80
NVSEF's Revenue Growth (3Y)(%) is ranked lower than
64% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.10 vs. NVSEF: 1.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVSEF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.9  Med: 4.40 Max: 73.5
Current: 1.8
-3.9
73.5
EBITDA Growth (3Y)(%) -7.20
NVSEF's EBITDA Growth (3Y)(%) is ranked lower than
75% of the 543 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.90 vs. NVSEF: -7.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVSEF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.6  Med: 0.80 Max: 82.7
Current: -7.2
-7.6
82.7
EPS Growth (3Y)(%) -6.80
NVSEF's EPS Growth (3Y)(%) is ranked lower than
72% of the 496 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. NVSEF: -6.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVSEF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.1  Med: 3.50 Max: 82
Current: -6.8
-7.1
82
» NVSEF's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-21)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NVSEF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 27.56
NVSEF's P/E(ttm) is ranked higher than
88% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.10 vs. NVSEF: 27.56 )
Ranked among companies with meaningful P/E(ttm) only.
NVSEF' s P/E(ttm) Range Over the Past 10 Years
Min: 7.87  Med: 16.16 Max: 27.56
Current: 27.56
7.87
27.56
Forward P/E 15.38
NVSEF's Forward P/E is ranked higher than
59% of the 69 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.85 vs. NVSEF: 15.38 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 27.76
NVSEF's PE(NRI) is ranked higher than
52% of the 536 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.01 vs. NVSEF: 27.76 )
Ranked among companies with meaningful PE(NRI) only.
NVSEF' s PE(NRI) Range Over the Past 10 Years
Min: 10.63  Med: 18.06 Max: 31.15
Current: 27.76
10.63
31.15
Price/Owner Earnings (ttm) 16.77
NVSEF's Price/Owner Earnings (ttm) is ranked higher than
90% of the 261 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.99 vs. NVSEF: 16.77 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
NVSEF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.18  Med: 15.39 Max: 22.47
Current: 16.77
7.18
22.47
P/B 2.52
NVSEF's P/B is ranked higher than
60% of the 727 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.94 vs. NVSEF: 2.52 )
Ranked among companies with meaningful P/B only.
NVSEF' s P/B Range Over the Past 10 Years
Min: 1.69  Med: 2.49 Max: 4.14
Current: 2.52
1.69
4.14
P/S 3.73
NVSEF's P/S is ranked lower than
61% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.78 vs. NVSEF: 3.73 )
Ranked among companies with meaningful P/S only.
NVSEF' s P/S Range Over the Past 10 Years
Min: 1.89  Med: 3.26 Max: 5.01
Current: 3.73
1.89
5.01
PFCF 22.57
NVSEF's PFCF is ranked higher than
58% of the 194 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.93 vs. NVSEF: 22.57 )
Ranked among companies with meaningful PFCF only.
NVSEF' s PFCF Range Over the Past 10 Years
Min: 7.05  Med: 16.77 Max: 26.69
Current: 22.57
7.05
26.69
POCF 15.87
NVSEF's POCF is ranked higher than
58% of the 253 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.08 vs. NVSEF: 15.87 )
Ranked among companies with meaningful POCF only.
NVSEF' s POCF Range Over the Past 10 Years
Min: 5.77  Med: 13.06 Max: 19.3
Current: 15.87
5.77
19.3
EV-to-EBIT 23.84
NVSEF's EV-to-EBIT is ranked lower than
57% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.82 vs. NVSEF: 23.84 )
Ranked among companies with meaningful EV-to-EBIT only.
NVSEF' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 15.50 Max: 26.6
Current: 23.84
8.5
26.6
EV-to-EBITDA 15.95
NVSEF's EV-to-EBITDA is ranked higher than
54% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.62 vs. NVSEF: 15.95 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVSEF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 12.15 Max: 18.1
Current: 15.95
7.3
18.1
Shiller P/E 16.22
NVSEF's Shiller P/E is ranked higher than
88% of the 140 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.65 vs. NVSEF: 16.22 )
Ranked among companies with meaningful Shiller P/E only.
NVSEF' s Shiller P/E Range Over the Past 10 Years
Min: 10.27  Med: 14.82 Max: 22.83
Current: 16.22
10.27
22.83
Current Ratio 0.83
NVSEF's Current Ratio is ranked lower than
89% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.41 vs. NVSEF: 0.83 )
Ranked among companies with meaningful Current Ratio only.
NVSEF' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.40 Max: 2.83
Current: 0.83
0.83
2.83
Quick Ratio 0.59
NVSEF's Quick Ratio is ranked lower than
88% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. NVSEF: 0.59 )
Ranked among companies with meaningful Quick Ratio only.
NVSEF' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.15 Max: 2.48
Current: 0.59
0.59
2.48
Days Inventory 133.94
NVSEF's Days Inventory is ranked lower than
61% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.44 vs. NVSEF: 133.94 )
Ranked among companies with meaningful Days Inventory only.
NVSEF' s Days Inventory Range Over the Past 10 Years
Min: 117.85  Med: 155.69 Max: 183.42
Current: 133.94
117.85
183.42
Days Sales Outstanding 62.50
NVSEF's Days Sales Outstanding is ranked higher than
62% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.18 vs. NVSEF: 62.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVSEF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.31  Med: 63.90 Max: 70.59
Current: 62.5
56.31
70.59
Days Payable 98.46
NVSEF's Days Payable is ranked higher than
74% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.90 vs. NVSEF: 98.46 )
Ranked among companies with meaningful Days Payable only.
NVSEF' s Days Payable Range Over the Past 10 Years
Min: 95.93  Med: 116.45 Max: 135.35
Current: 98.46
95.93
135.35

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.47
NVSEF's Dividend Yield is ranked higher than
90% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.56 vs. NVSEF: 3.47 )
Ranked among companies with meaningful Dividend Yield only.
NVSEF' s Dividend Yield Range Over the Past 10 Years
Min: 1.47  Med: 3.23 Max: 5.11
Current: 3.47
1.47
5.11
Dividend Payout 0.97
NVSEF's Dividend Payout is ranked lower than
90% of the 365 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. NVSEF: 0.97 )
Ranked among companies with meaningful Dividend Payout only.
NVSEF' s Dividend Payout Range Over the Past 10 Years
Min: 1.12  Med: 1.67 Max: 3.22
Current: 0.97
1.12
3.22
Dividend Growth (3y) 5.40
NVSEF's Dividend Growth (3y) is ranked lower than
56% of the 280 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. NVSEF: 5.40 )
Ranked among companies with meaningful Dividend Growth (3y) only.
NVSEF' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 6.80 Max: 18.5
Current: 5.4
0
18.5
Forward Dividend Yield 3.47
NVSEF's Forward Dividend Yield is ranked higher than
87% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. NVSEF: 3.47 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.84
NVSEF's Yield on cost (5-Year) is ranked higher than
89% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.32 vs. NVSEF: 4.84 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVSEF' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.05  Med: 4.51 Max: 7.13
Current: 4.84
2.05
7.13
3-Year Average Share Buyback Ratio 0.20
NVSEF's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 465 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -3.30 vs. NVSEF: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVSEF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.2  Med: 0.70 Max: 41.9
Current: 0.2
-2.2
41.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 30.50
NVSEF's Price/Tangible Book is ranked lower than
91% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. NVSEF: 30.50 )
Ranked among companies with meaningful Price/Tangible Book only.
NVSEF' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.16  Med: 4.22 Max: 12455
Current: 30.5
0.16
12455
Price/Projected FCF 1.20
NVSEF's Price/Projected FCF is ranked higher than
84% of the 298 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.83 vs. NVSEF: 1.20 )
Ranked among companies with meaningful Price/Projected FCF only.
NVSEF' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.66  Med: 1.06 Max: 2.52
Current: 1.2
0.66
2.52
Price/Median PS Value 1.14
NVSEF's Price/Median PS Value is ranked higher than
54% of the 624 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.18 vs. NVSEF: 1.14 )
Ranked among companies with meaningful Price/Median PS Value only.
NVSEF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.64  Med: 1.15 Max: 3.11
Current: 1.14
0.64
3.11
Price/Graham Number 6.12
NVSEF's Price/Graham Number is ranked lower than
79% of the 445 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.13 vs. NVSEF: 6.12 )
Ranked among companies with meaningful Price/Graham Number only.
NVSEF' s Price/Graham Number Range Over the Past 10 Years
Min: 0.43  Med: 1.92 Max: 81.67
Current: 6.12
0.43
81.67
Earnings Yield (Greenblatt) (%) 4.20
NVSEF's Earnings Yield (Greenblatt) (%) is ranked higher than
60% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. NVSEF: 4.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVSEF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.8  Med: 6.40 Max: 11.8
Current: 4.2
3.8
11.8
Forward Rate of Return (Yacktman) (%) 3.33
NVSEF's Forward Rate of Return (Yacktman) (%) is ranked lower than
58% of the 315 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.27 vs. NVSEF: 3.33 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVSEF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1  Med: 14.30 Max: 71.6
Current: 3.33
1
71.6

More Statistics

Revenue(Mil) $50387
EPS $ 7.28
Beta0.77
Short Percentage of Float0.00%
52-Week Range $71.00 - 106.53
Shares Outstanding(Mil)2381.28

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 48,982 50,424 55,501
EPS($) 4.88 5.08 6.14
EPS without NRI($) 4.88 5.08 6.14

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:JNJ, NYSE:PFE, NYSE:MRK, NYSE:BMY, XPAR:SAN » details
Traded in other countries:NVS.Argentina, NOT.Germany, NVS N.Mexico, NOVN.Switzerland, 0HKE.UK, NVS.USA,
Novartis AG was incorporated on February 29, 1996 under the Swiss laws. On December 20, 1996, its predecessor companies, Ciba-Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. The Company is engaged in the research, development, manufacturing and marketing of healthcare and pharmaceuticals products. The Company's portfolio includesmedicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company's wholly-owned businesses are organized into six global operating divisions, and report teir results in the following five segments; Pharmaceuticals: Innovative patent-protected prescription medicines, Alcon: Surgical, ophthalmic pharmaceutical and vision care products, Sandoz: Generic pharmaceuticals, Vaccines and Diagnostics: Preventive human vaccines and blood testing diagnostics, Consumer Health: OTC (over-the-counter medicines) and Animal Health. The Pharmaceuticals division researches, develops, manufactures, distributes and sells patented prescription medicines and is organized in the following business franchises: Primary Care, consisting of Primary Care medicines and Established Medicines; and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The manufacture of the products is complex and heavily regulated by governmental health authorities, which means that supply is never guaranteed. If the Company or its third party suppliers fail to comply with applicable regulations then there could be a product recall or other shutdown or disruption of its production activities. The Company is subject to the laws of Switzerland, in particular Swiss company and securities laws, and to the securities laws of the United States as applicable to foreign private issuers of securities.
» More Articles for NVSEF

Headlines

Articles On GuruFocus.com
Samuel Isaly Trades in Health Care Stocks in 1st Quarter Apr 27 2016 
Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
Dan Loeb's Third Point Portfolio Highly Concentrated Apr 01 2016 
Daniel Loeb's Third Point Portfolio Highly Concentrated Mar 31 2016 
Valeant's Share Price Continues to Decline Feb 05 2016 
10 Fund Managers Are Totally Wrong on GlaxoSmithKline Jan 26 2016 
Guru Stocks at 52-Week Lows Jan 26 2016 
Berkshire Hathaway, Wells Fargo, China Mobile, Novartis, Bank of America Reach 52-Week Lows Jan 11 2016 
Berkshire Hathaway, China Mobile, Novartis, Oracle, PetroChina Near 52-Week Lows Jan 04 2016 

More From Other Websites
Analysts’ Recommendations: Most Rate Novartis a ‘Buy’ Apr 27 2016
[$$] Sir Andrew Witty fuels GSK turnround hopes with results boost Apr 27 2016
Drugs giant GSK reports slump in profits Apr 27 2016
Glaxo Profit Rises for First Time Since 2013, Tops Estimates Apr 27 2016
Novartis’s Pharmaceutical Revenue Reported Growth in 1Q16 Apr 27 2016
Novartis Reported Operational Growth in Its 1Q16 Earnings Apr 25 2016
Novartis’s 1Q16 Earnings Got a Neutral Response from Investors Apr 25 2016
April 25 Premarket Briefing: 10 Things You Should Know Apr 25 2016
Novartis could refuel M&A machine with $14 billion Roche stake sale Apr 25 2016
Novartis to prepare the sale of its Roche stake, paper says Apr 25 2016
Novartis to prepare the sale of its Roche stake, paper says Apr 25 2016
[$$] Big Pharma Gets Solace From Europe Apr 24 2016
[$$] Big Pharma hunts for malaria drugs to fight mosquito resistance Apr 24 2016
Novartis to prepare the sale of its Roche stake: Sonntagszeitung Apr 24 2016
Does Biotech’s Recent Bounce Have Legs? Apr 22 2016
Novartis (NVS) Q1 Earnings Miss; Gleevec Hit by Generics Apr 22 2016
Is U.S. Drug Pricing Debate Leaving Europe Feeling Good? Apr 22 2016
[$$] Novartis Earnings Fall on Slide in Cancer-Drug Sales Apr 21 2016
Novartis CEO says 'legacy' bribery allegations provisioned for Apr 21 2016
Novartis CEO says "legacy" bribery allegations provisioned for Apr 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK